Yu, M.-W.; Lin, C.-L.; Liu, C.-J.; Wu, W.-J.; Hu, J.-T.; Huang, Y.-W.
Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Cancers 2022, 14, 6012.
https://doi.org/10.3390/cancers14236012
AMA Style
Yu M-W, Lin C-L, Liu C-J, Wu W-J, Hu J-T, Huang Y-W.
Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Cancers. 2022; 14(23):6012.
https://doi.org/10.3390/cancers14236012
Chicago/Turabian Style
Yu, Ming-Whei, Chih-Lin Lin, Chun-Jen Liu, Wan-Jung Wu, Jui-Ting Hu, and Yi-Wen Huang.
2022. "Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B" Cancers 14, no. 23: 6012.
https://doi.org/10.3390/cancers14236012
APA Style
Yu, M.-W., Lin, C.-L., Liu, C.-J., Wu, W.-J., Hu, J.-T., & Huang, Y.-W.
(2022). Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Cancers, 14(23), 6012.
https://doi.org/10.3390/cancers14236012